Sanglifehrins A and B exhibit a 10~20 fold higher affinity for CypA than CsA, whereas the affinity of sanglifehrins C and D for CypAis comparable to that of CsA. Sanglifehrins exhibit a lower immunosuppressive activity than CsAwhen tested in the mixed lymphocyte reaction. Their in vitro activity indicates that they belong to a novel class of immunosuppressants.
Cyclosporin A (CsA), an undecapeptide produced by various fungi1), exerts its immunosuppressive effects by binding to the intracellular binding protein cyclophilin A (CypA)2). Although this binding is required, it is not sufficient for the immunosuppressive activity. The CsACypA complex binds to another protein, the serinethreonine phosphatase calcineurin, whose enzymatic activity is inhibited3 ' 4) . This leads to the inhibition of T cell activation by preventing transcription of early T cell genes including genes encoding lymphokines like interleukin-2, the main growth factor for T cells5).
To identify compounds which might potentially interfere with other signalling pathways not involving calcineurin and which thereby might exert novel biological effects, a screening for novel cyclophilin-binding entities was performed with methanolic extracts of actinomycete broths. This approach was stimulated by findings related to two other immunosuppressive drugs, namely FK506 and rapamycin. Both drugs bind to the pp. 466 -473 same intracellular binding protein FKBP6). However, the corresponding drug-FKBP complexes interact with two different effector molecules: the FK506-FKBP complex binds to calcineurin as does the CsA-CypA complex.
Consequently, FK506 inhibits T cell activation via the same signalling pathway as CsA does7). In contrast, the rapamycin-FKBP complex binds to a different protein, i.e. mTOR, which is involved in growth factor mediated intracellular signal-transduction pathways8). Accordingly, rapamycin has a different activity profile, inhibiting the clonal expansion ofT cells at a later stage. The effect of rapamycin is not restricted to T cells; in general, rapamycin inhibits the proliferation of cells in response to growth factors9). Screening for microbial broth extracts blocking the CsA-CypAinteraction was performed with a competitive ELISA. Amongmore than 12,000 actinomycete extracts tested (4,000 strains from various origin in three media) three showed activity in this binding assay. One strain VOL.52 NO.5 THE JOURNAL OF ANTIBIOTICS produced the metabolites cymbimycin A and B10), and one of the others, S92-3081 10A of the genus Streptomyces sp., lead to the discovery of the sanglifehrins.
Materials and Methods

Characterization of the Producing Strain
The morphology of the strain was ascertained by light microscopy and scanning electron microscopy. 
Cyclophilin
Binding Assay The ability of a compoundto bind to cyclophilin was determined by means of a competitive binding assay (cyclophilin binding assay, GBA)as described previously14'1^.
A D-Lys8-cyclosporin-derivative was coupled to bovine serum albumin and coated onto polyvinyl microtiter plate (1~2 //g/ml in phosphate buffered saline (PBS) for 2 hours at 37°C After saturation of the plate with 2% BSAin PBS (1hour at 37°C) and washings with 0.05% Tween 20 containing PBS and three times with PBS, biotinylated recombinant cyclophilin A, B or C were incubated overnight at 4°C (75ng/ml CYP-A, 40 ng/ml CYP-B and 250 ng/ml CYP-C in 1%BSA-PBS, as titrated on BSA-CsAto achieve similar absorbance signals).
After washing, the amount of bound biotinylated cyclophilin was assessed by incubation with a streptavidin coupled to alkaline phosphatase (Jackson Immunoresearch Labs, Inc, 1 :7500 in 1%BSA-PBS, 2 hours at 37°C), followed by washing. The absorbance at 405 nmwas measured after hydrolysis of/?-nitro-phenyl phosphate (1 mg/ml in diethanolamine 1m buffer pH 9.6, for 1-2 hours at 37°C). In the competitive assay, biotinylated cyclophilins were incubated in the presence of the microbial extracts or compounds (overnight at 4°C). Free cyclosporin A was used as a reference compound. Solutions ofCsA (1 mg/ml in ethanol) and sanglifehrinanalogues (1 mg/ml methanolic solution) were immediately added to the CyP solutions (at 1 : 10 to 1 : 100 dilution) and further 10-fold dilutions were made directly in the microtiter plate. After washings to remove the unbound CyP, the assay continued as above. Binding of a compound to the biotin- Based on physical and spectroscopic data (presented in the accompanying paper18) the compounds belong to a novel class of microbial compounds. The structures of 471 these four sanglifehrins are given in Figure 2 . The characterization of additional natural analogues is pursued. The wild strain produced in addition large amounts of mycotrienins.
Biological Properties
The relative affinity of sanglifehrins for CyPAwas determined in a competitive binding assay (see Material and Methods). CsA was tested in parallel and taken as reference. The results, expressed as relative IC50, which is the ratio between IC50 sanglifehrin and IC50 CsA, are shown in Table 3 . The relative are shown in Table 3 . Sanglifehrins A and B were shown to bind very tighly to CyPA, their affinities being twenty times higher than that of CsA (the absolute IC50 of Cyclosporine A in these experiments was 80~160ng/ml). The binding affinity to cyclophilin B and C was also measured ( The results are shown in Table 4 . Sanglifehrin A and B showed IC50 values of 170nM and 102nM, respectively. factor-induced proliferation ofmurine bone marrow cells was not affected by sanglifehrin Aat concentrations up to 5000nM, demonstrating a specificity in the mode of action. The sanglifehrins did not inhibit the phosphatase activity of calcineurin3'4), the target of the cyclophilin/ cyclosporin A complex19'20). Accordingly, they showed no activity in the reporter gene assay for IL-2 gene expression (data not shown). These results indicate that this compound class has a different mode of action than cyclosporin A. Additional studies related to the mechanismof action, to the biological effects and to selectivity of these novel microbial compounds are being pursued; from the data will be reported elsewhere.
